Exagen Inc. (XGN) AI Stock Analysis
XGN AI stock analysis summary
AI ResearchExagen Inc. (XGN) is a commercial-stage diagnostics company that develops testing products under the AVISE brand for autoimmune and related conditions. In FY2025, revenue grew 19.7% to $66.6M, though the company recorded a net loss of -$20.0M. Over the trailing twelve months, revenue reached $71.1M with an operating margin of -8.6%.
- Market cap
- $187.0M
- Revenue (TTM)
- $71.1M
- P/E
- —
- 1Y return
- -34.4% S&P 500 16.8%
- Avg. target
- $10.29 33.2% vs last close
Bull case
- Annual revenue expanded by 19.7% in FY2025 to $66.6M, followed by 15.9% year-over-year quarterly revenue growth in the period ending June 30, 2026.
- All 7 covering analysts rate the stock a Strong Buy, with a mean price target of $10.29 implying 33.2% upside from the last close of $7.72.
- Operating margin has improved from -101.1% in FY2022 to -21.1% in FY2025, reaching -8.6% on a trailing twelve months basis.
Bear case
- Exagen has remained unprofitable, recording a net loss of -$20.0M in FY2025 and a trailing twelve months net margin of -26.6%.
- Cash flow remains in deficit, evidenced by free cash flow of -$14.3M in FY2025 and a debt-to-equity ratio of 2.09 as of June 30, 2026.
- Longer-term share performance has lagged the broader market, with a 5-year return of -38.9% compared to an 83.0% gain for the S&P 500 (SPY).
What Exagen does
Exagen Inc. specializes in the development and commercialization of advanced testing products leveraging its proprietary cell-bound complement activation products technology. Operating under the AVISE brand in the United States, Exagen empowers rheumatologists in the comprehensive management of autoimmune and autoimmune-related diseases, such as systemic lupus erythematosus, rheumatoid arthritis, and connective tissue diseases. Its flagship offering is the AVISE CTD test for differential diagnosis, complemented by specialized tools including AVISE Lupus, AVISE APS, AVISE SLE Prognostic, and AVISE Vasculitis AAV. Exagen also collaborates with research institutions like Allegheny Health Network Research Institute to discover novel biomarkers.
Growth and profitability
Exagen generated a 5-year revenue CAGR of 9.7% from FY2020 through FY2025. Annual revenue expanded from $48.3M in FY2021 to $52.5M in FY2023, $55.6M in FY2024, and $66.6M in FY2025, marking 19.7% growth in FY2025. Gross margin stood at 58.3% in FY2025, compared to 57.4% in FY2021. Operating margins remained negative but improved from -49.8% in FY2021 and -101.1% in FY2022 to -21.1% in FY2025. Net income was -$20.0M in FY2025 compared to -$26.9M in FY2021. For the trailing twelve months ending June 30, 2026, revenue reached $71.1M, with quarterly revenue growth of 15.9% year-over-year.
Balance sheet and cash flow
As of June 30, 2026, Exagen held $24.6M in cash and short-term investments and $25.5M in total debt, bringing net debt to $959,000. Shareholders' equity was $12.2M against total assets of $51.9M, with a debt-to-equity ratio of 2.09 and a current ratio of 3.18. In FY2025, operating cash flow was -$13.6M, free cash flow was -$14.3M, and capital expenditures were $641,000. Over five years, the company's share count increased by 42.4%.
Valuation and performance
At $7.72 per share on October 16, 2026, Exagen has a market capitalization of $187.0M and an enterprise value of $208.6M. The stock trades at a price-to-sales multiple of 2.6x and an enterprise value-to-revenue multiple of 2.9x, which sit below the median price-to-sales ratio of 4.1x for its US-listed Healthcare peers. Its price-to-book ratio is 17.0x. Over the past year, Exagen shares returned -34.4%, trailing the S&P 500 (SPY) return of 16.8%, although its year-to-date return was 27.0%.
What analysts expect
Wall Street coverage includes 7 Strong Buy ratings and no Buy, Hold, Sell, or Strong Sell ratings. The mean price target is $10.29, representing 33.2% upside from the last close of $7.72. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $73.9M and an EPS of -$0.63. For the following fiscal year, 2 analysts anticipate revenue of $81.5M, reflecting 10.3% growth, alongside an EPS of -$0.47. Exagen beat EPS estimates in 2 of the last 4 quarters, with its next earnings report scheduled for November 3, 2026.
Key risks and what to watch
- Exagen's cash and short-term investments of $24.6M are paired with negative annual operating cash flow of -$13.6M in FY2025, posing ongoing cash burn risks.
- Shareholder equity is exposed to dilution risk, as the total share count rose 42.4% over the past five years.
- The stock exhibits heightened volatility, as indicated by a beta of 2.12 and a 52-week trading range between $2.59 and $12.23.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this XGN AI stock analysis
This page is an AI-written research summary of Exagen Inc. (XGN). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: XGN income statement, XGN balance sheet, XGN key metrics, XGN analyst forecast, XGN chart. See the XGN stock overview for the latest quote and news.
XGN AI stock analysis FAQ
What does Exagen Inc. do?
Exagen develops and commercializes advanced diagnostic and prognostic tests for rheumatologists under the AVISE brand. Its products assist in managing autoimmune conditions like systemic lupus erythematosus, rheumatoid arthritis, and connective tissue diseases.
Does Exagen pay a dividend?
Exagen does not pay a dividend. The company directs its resources toward business operations, reporting capital expenditures of $641,000 in FY2025.
What are analysts forecasting for Exagen's revenue and earnings?
For the fiscal year ending December 31, 2026, analysts estimate revenue of $73.9M and an EPS of -$0.63. For next fiscal year, 2 analysts project revenue of $81.5M and an EPS of -$0.47.
What is Exagen's debt position?
As of June 30, 2026, Exagen held $25.5M in total debt against $24.6M in cash and short-term investments, resulting in net debt of $959,000 and a debt-to-equity ratio of 2.09.